Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clini...
Leadership
Jerome Benedict Durso
Chairman, CEO & President
M. Scot Roberts Ph.D.
Chief Scientific Officer
Christophe Arbet-Engels M.B.A., M.D., Ph.D.
Chief Medical Officer
Gregory L. Weaver CPA, M.B.A.
Chief Financial Officer
Andrew Shutterly M.S.
Principal Financial & Accounting Officer and Corporate Controller
